Buy or sell PHARMAJET stock pre IPO via an EquityZen fund
EquityZen is a marketplace for shares of proven pre IPO tech companies
PharmaJet's devices provide for fixed dose needle-free jet injection for all three tissue depths (IM, SC, & ID).
About PHARMAJET Stock
PharmaJet is a user-friendly, inexpensive device for fluid injection into the body without a needle. Able to compete with traditional needle-syringe delivery, which inherently poses costly needle-stick, re-use and pass-along disease risk, the technology creates a positive ROI back for every injection. Unique in the field of jet injection because of its ability to reach all target tissues (IM, SC--0.5 mL, and ID--0.1 mL) accurately and comfortably, supported by wide regulatory claims (global and country specific) PharmaJet's platforms are the only commercially available devices that effectively address the 3 B annual immunization market. In addition to standard depth and dose delivery of any fluid, PharmaJet also has the ability to hyper-stimulate an improved immune response. The intradermal platform reduces the dose of vaccine by 60-80%, delivering into a 1.5-3mm tissue space in less than 1/10th of a second and achieving the same or superior immune response to a full intramuscular dose. For nucleic acid vaccines, both device platforms provide rapid delivery that helps negate the need for electroporation, while providing a several fold improved immune response versus needle based delivery. This is helping to facilitate vaccines gaining regulatory approval for solutions to pandemic threats and cancer vaccines, with a simple push and click.
Vice-Chairman, Global Business Development Officer, Co-Founder
Chairman and Chief Executive Officer
Chief Operating Officer
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase